Lead Product(s): LC51-0255
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
The ePoster highlighted the safety, pharmacokinetics and mechanistic properties of LC51-0255. A Phase II trial in patients with moderate to severely active ulcerative colitis is currently in development.